688331.SHG RemeGen Co. Ltd. A
- Market cap
- CNY 54.0B
- P/E
- 8.2x
- P/B
- 5.39x
- ROE
- 30.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 688331.SHG undervalued?
Graham number688331.SHG trades 39.7% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
RemeGen Co. Ltd. A fundamental analysis
No fundamental analysis for RemeGen Co. Ltd. A yet.
RemeGen Co. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About RemeGen Co. Ltd. A
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, ur…
Full company profileRemeGen Co. Ltd. A financial statements
RemeGen Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 11.3M | 2.68M | -486K | 1.42B | 772M | 1.08B | 1.72B | 3.25B |
| Gross Profit | 2.39M | -42.5M | -77.6M | 1.36B | 500M | 826M | 1.37B | 3.25B |
| Operating Income | -243M | -421M | -708M | 163M | -995M | -1.50B | -1.46B | 721M |
| EBITDA | -208M | -345M | -619M | 348M | -868M | -1.31B | -1.16B | 940M |
| Net Income | -270M | -430M | -698M | 276M | -999M | -1.51B | -1.47B | 709M |
| EPS | -0.56 | -1.65 | -1.71 | 0.57 | -1.88 | -2.80 | -2.73 | 1.29 |
| Balance Sheet | ||||||||
| Total Assets | 531M | 689M | 4.12B | 4.16B | 6.02B | 5.53B | 5.50B | 7.25B |
| Total Liabilities | 1.03B | 921M | 523M | 713M | 1.04B | 2.09B | 3.51B | -2.32B |
| Shareholders' Equity | -498M | -232M | 3.59B | 3.45B | 4.98B | 3.44B | 1.99B | 2.32B |
| Cash & Short-term Investments | 6.03M | 37.5M | 2.77B | 1.76B | 2.07B | 709M | 760M | 2.42B |
| Total Debt | 863M | 653M | 198M | 103M | 165M | 1.26B | 2.67B | 1.47B |
| Cash Flow | ||||||||
| Operating Cash Flow | -128M | -283M | -660M | 264M | -1.26B | -1.50B | -1.18B | 56.2M |
| Capital Expenditure | 83.7M | 65.2M | 481M | 617M | 758M | 853M | 265M | 200M |
| Free Cash Flow | -212M | -348M | -1.14B | -354M | -2.02B | -2.35B | -1.44B | -144M |
| Ratios | ||||||||
| ROE | - | - | -19.4% | 8.0% | -20.1% | -44.0% | -73.9% | 30.5% |
| ROA | -50.8% | -62.4% | -16.9% | 6.6% | -16.6% | -27.3% | -26.7% | 9.8% |
| Net Profit Margin | -2,384.5% | -16,047.4% | - | 19.4% | -129.4% | -139.5% | -85.5% | 21.8% |
| Debt to Equity | - | - | 0.05x | 0.03x | 0.03x | 0.37x | 1.34x | 0.63x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
RemeGen Co. Ltd. A dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | CNY 69.8M | 0.13 | - |
| 2023 | CNY 15.4M | 0.03 | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns RemeGen Co. Ltd. A
- Insiders 54.12%
- Institutions 11.66%
- Public & others 34.22%
- Shares outstanding 356M
- Free float 344M
RemeGen Co. Ltd. A company profile
- Company name
- RemeGen Co. Ltd. A
- Ticker
- 688331.SHG
- ISIN
- CNE100005B03
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3,048
- Fiscal year end
- December
- Address
- 58 Middle Beijing Road, Yantai, China
- Phone
- 86 53 5611 3511
- Website
- remegen.com
About RemeGen Co. Ltd. A
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People's Republic of China.
RemeGen Co. Ltd. A management
10- Mr. Weidong WangCo-Founder & Executive Chairman · born 1959
- Dr. Jianmin FangCo-Founder, CEO, GM, Member of Scientific Advisory Board & Executive Director · born 1962
- Mr. Shaojing TongCFO & Company Secretary · born 1971
- Mr. Qingkai WenExecutive Director & Board Secretary · born 1966
- Mr. Kaisheng HuangChief Operating Officer
- Jian Liang WeiAccounting Supervisor
- Dr. Marie ZhuChief Technical Officer
- Dr. Xiaoming Yang Ph.D.Chief Manufacturing Officer · born 1964
- Dr. Ming Shi M.D., Ph.D.Chief Medical Officer · born 1967
- Ms. Yi FangExecutive Director